Search This Blog

Showing posts with label DSM. Show all posts
Showing posts with label DSM. Show all posts

Tuesday, August 26, 2014

IACC Statement Regarding Scientific, Practice and Policy Implications of Changes in the Diagnostic Criteria for Autism Spectrum Disorder

The DSM-5 criteria were published in May 2013.1, 2 Although the DSM-5 diagnostic criteria are intended primarily for use by clinicians and researchers in their diagnostic assessments, the IACC is aware that it is important to also remember that these the criteria also have a direct impact on people who have the disorders and their families, and their ability to assess symptoms and obtain services that can help them optimize their health, well-being and quality of life. Any revision of the diagnostic criteria must be made with great care so as to not have the unintended consequence of reducing critical services aimed at improving the ability of persons with autism. In this statement, the IACC describes a range of research, practice, and policy implications that arise as a result of the changes in theDSM criteria which deserve consideration as the DSM-5 is implemented in research, clinical, and educational settings.
Changes in the DSM Criteria
Starting with the DSM-III in 1980, autism was categorized as a Pervasive Developmental Disorders (PDD). In an effort to reflect what has been learned through research and practice since that time, the DSM-5 released in 2013 removed the PDD category and the accompanying subtypes (Autistic Disorder, Asperger Disorder, Childhood Disintegrative Disorder and Pervasive Developmental Disorder – Not Otherwise Specified) with a single disorder, Autism Spectrum Disorder (ASD). The DSM-5 criteria place greater emphasis on the two core symptom domains of ASD (social communication and restrictive, repetitive behaviors), and no longer consider verbal abilities as a diagnostic feature. Other changes included adding ratings of the severity of the two symptom domains and several clinical specifiers. These specifiers provide information about etiology, co-morbidities (e.g., intellectual disability, language delay, and medical conditions such as seizures), and pattern of onset.
Since ASD continues to be defined by a pattern of developmental and behavioral symptoms, changes to the diagnostic criteria come with potential trade-offs. One goal of the recent revisions was to improve specificity of the ASD diagnosis, reducing the number of false positive cases. However, concerns exist that this increased specificity may have gone too far in reducing the sensitivity of the ASD diagnosis, increasing the number of false negative cases. For example, removing a specific age cut-off for diagnosis was intended to improve the sensitivity of theDSM-IV criteria (which had required symptom onset by 3 years of age). By DSM-5's more inclusive criterion, "Symptoms must be present in the early developmental period but may not become fully manifest until social demands exceed limited capacities, or may be masked by learned strategies in later life" may reduce diagnostic specificity by expanding the list of differential diagnoses that must be considered. The inclusion of historical information also may have unintended consequences on sensitivity and specificity.
Another major change in DSM-5 was the addition of a new diagnosis category, Social Communication Disorder (SCD)which applies to individuals who exhibit persistent difficulty with the social use of verbal and nonverbal communication that cannot be explained by low cognitive ability. The symptoms of SCD have significant overlap with those of the ASD social communication domain, but the two disorders are considered to be unique and separate from each other. The distinction is clarified in the DSM-5 criteria, which note that ASD must be ruled out before a diagnosis of SCD can be considered. However, there is limited published information on SCD with a research basis primarily in the condition previously studied as Pragmatic Language Disorder (PLD). While SCD includes PLD, there is much to learn about the definition, measurement, scope, reliability, and validity of SCD as a diagnosed condition.

Federal Autism Panel Raises Concerns Over DSM Changes

A federal advisory panel is urging clinicians to be careful when applying new diagnostic criteria for autism in order to ensure that no one is denied needed services.
Dramatic changes to the definition of autism took effect last year with publication of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders. Under the new definition, autistic disorder, Asperger’s syndrome, childhood disintegrative disorder and pervasive developmental disorder, not otherwise specified were folded under an umbrella classification of “autism spectrum disorder” with clinicians specifying a level of severity.
Now the Interagency Autism Coordinating Committee — a federal advisory panel comprised of government officials and members of the autism community — is highlighting a number of implications that may result from the shift.
In practical terms, the IACC is cautioning clinicians, noting that the new diagnostic criteria have not yet been rigorously tested in young kids, adults and individuals from various ethnic populations.
The group is also citing concerns about the reliability of severity ratings used to denote where an individual falls on the autism spectrum and the applicability of the new criteria for children under age 3 who may not yet fully display symptoms despite a need for early intervention.
“Services should be based on need rather than diagnosis; it would not be appropriate for a child to be denied ASD-specific services because he or she does not meet full DSM-5 criteria if a qualified clinician or educator determines that the child could benefit from those services,” the panel said in its report, adding that the updated DSM requires that all those who previously had an autism diagnosis under the old diagnostic criteria retain that label going forward.
The IACC said further research is needed to determine how reliable and valid the DSM-5 definition is and to weigh the impact of the changes on diagnosis, prevalence and access to services.

Monday, August 18, 2014

Archived Webinar - DSM-5: A Spotlight On Autism Spectrum Disorder and Intellectual Disability

Speakers
Jarrett Barnhill, MD, DFAPA, FAACAP
Dr. Barnhill specializes in the diagnosis and pharmacological treatment of autism and other developmental disabilities, and other neuropsychiatric disorders such as Tourette’s syndrome and other movement disorders as well as psychiatric problems in patients with epilepsy. He is Director of the UNC Developmental Neuropharmacology Clinic and a consultant in neuropsychiatry at Dorothea Dix Hospital, the Murdoch Center in Butner, NC, the Caswell Center in Kinston, NC, and Residential Services, Inc. in Chapel Hill, NC, as well as for Autism services.

Marc Tassé, PhD
Dr. Tassé is the Director of the Ohio State University (OSU) Nisonger Center, a University Center for Excellence in Developmental Disabilities (UCEDD). He is also a Professor of Psychology and Psychiatry at OSU. Dr. Tassé’s experience includes 20 years of experience in conducting research and providing clinical services in the field of intellectual disability (formerly known as mental retardation) and related developmental disabilities. Dr. Tassé has conducted over 100 trainings, workshops, and presentations related to intellectual disability. His publication record includes more than 70 articles in peer-reviewed journals, chapters, and books in the area of intellectual and developmental disabilities.

View the archived webinar here.